Original Article

Beneficial effects of Galectin-9 on allergen-specific sublingual immunotherapy in a *Dermatophagoides farinae*-induced mouse model of chronic asthma

Masaki Ikeda a, Shigeki Katoh a,*, Hiroki Shimizu a, Akira Hasegawa b, Katsuyo Ohashi-Doi b, Mikio Oka a

a Department of Respiratory Medicine, Kawasaki Medical School, Okayama, Japan
b Research Laboratories, Torii Pharmaceutical Co., Ltd., Chiba, Japan

A R T I C L E   I N F O

Article history:
Received 28 July 2016
Accepted 20 October 2016
Available online xxxx

Keywords:
Galectin-9
Mite allergen
Mouse
SLIT
TGF-β1

A B S T R A C T

Background: Allergen-specific sublingual immunotherapy is a potential disease-modifying treatment for allergic asthma. Galectin-9 (Gal-9), a β-galactoside-binding protein with various biologic effects, acts as an immunomodulator in excessive immunologic reactions by expanding regulatory T cells (Treg) and enhancing transforming growth factor (TGF)-β signaling. We investigated the efficacy of sublingually administered Gal-9 as an adjuvant to a specific allergen in a *Dermatophagoides farinae* (DF)-induced mouse model of chronic asthma.

Methods: BALB/c mice were intranasally sensitized with DF extract 5 days/week for 5 weeks, and then sublingual DF-allergen extract for 2 weeks (5 days/week). Three days after the final sublingual treatment, mice were intranasally challenged with DF extract. The early asthmatic response (EAR) was evaluated 5 min after the last DF challenge. Airway hyperresponsiveness (AHR) was assayed and bronchoalveolar lavage (BAL) was performed 24 h after the last allergen challenge. Serum IgE and cytokine levels, and number of inflammatory cells in the BAL fluid (BALF) were analyzed.

Results: Sublingual DF treatment in the presence of Gal-9, but not alone, significantly reduced AHR; EAR; number of eosinophils and interleukin-13 in the BALF; and serum IgE levels. BALF TGF-β1 levels were significantly increased in the presence of Gal-9 compared with DF alone. Treg depletion blocked the inhibitory effects of Gal-9 on the EAR, AHR, eosinophilic airway inflammation, and DF-specific serum IgE levels, and suppressed BALF TGF-β1 levels.

Conclusions: Gal-9 exhibited beneficial effects of sublingual DF-allergen-specific immunotherapy in a DF-induced mouse model of chronic asthma, possibly by Gal-9-induced TGF-β1 production in the lung.

Introduction

Asthma is a common respiratory disease characterized by reversible airway obstruction, airway hyperresponsiveness (AHR), and chronic airway inflammation with eosinophils. The majority of patients with asthma are well controlled by combined treatment with inhaled corticosteroids, long-acting β-agonists, and leukotriene receptor antagonists. These drugs have anti-inflammatory effects on chronic airway inflammation, but do not cure asthma. While allergen-specific immunotherapy might cure asthma, some problems, such as the administration route of the allergen, must be overcome. Recently, patients with allergic rhinitis and asthma induced by mite-allergen were treated with an allergen-specific sublingual immunotherapy (SLIT). The SLIT route could be beneficial toward curing these allergic airway diseases, but some difficulties remain.

Galectin-9 (Gal-9) is a β-galactoside binding animal lectin that induces various biologic reactions, such as cell chemotraction, activation, and apoptosis. Gal-9 functions as an immunomodulator in excessive immunologic reactions by expanding regulatory T cells (Treg) and immunosuppressive macrophages. Furthermore, Gal-9 and CD44 interactions enhance the stability and function of adaptive Treg through smad3-dependent mechanisms. The role of Gal-9 in allergic respiratory diseases, however, remains unclear.
In the present study, we developed a SLIT model of mite allergen-induced chronic asthma using the Dermatophagoides farinae (Df)-induced murine model of chronic asthma that we previously developed.12 We also used recombinant stable human Gal-913 as an adjuvant to the mite-allergen. The additive effects of Gal-9 in this SLIT model were evaluated by physiological examination, eosinophilic airway inflammation, and serum allergen-specific immunoglobulin levels, especially immunoglobulin IgE.

Methods

Animal model and sublingual immunotherapy

BALB/c mice were obtained from Charles River Laboratory (Yokohama, Japan). Female mice (8–12 weeks old) were intranasally sensitized with Df extract (40 µl of 1 mg/ml, LSI, Tokyo, Japan) 5 days/week for 5 weeks (Fig. 1). Negative control animals were intranasally exposed to phosphate-buffered saline (PBS) in a similar manner. Following intranasal administration of the Df extract for 5 weeks, SLIT was performed 5 days/week, twice daily, for 2 weeks (Fig. 1). The SLIT agents were PBS, Df-allergen extract (250 µg/day, Torii, Tokyo, Japan), and Df-allergen extract with recombinant human stable Gal-9 (0.1, 0.3, or 1.0 µg [3 µM], GalPharma, Takamatsu, Japan).13 For SLIT, the mouth of an anesthetized mouse was kept open by placing forceps under the tongue. We administered 10 µl of SLIT agent under the tongue with a micropipette that was kept in place for 1 min. In preliminary experiments, we used trypan blue to confirm that this method does not deliver the SLIT agent to the stomach or lung. Endotoxin contamination in the Df and Gal-9 solution was minimal, as previously described (<0.25 EU/mg).13,14 In this SLIT model, intranasal Df exposure is stopped during the SLIT because it is important for the SLIT to prevent allergen contact in patients with atopic asthma, as previously described.15,16 All experiments in the present study were performed under a protocol approved by the Institutional Animal Care and Use Committee of the Kawasaki Medical School.

Early asthmatic response (EAR) and airway hyperresponsiveness (AHR)

The early asthmatic response (EAR) was evaluated as the rate of increase (ΔsRaw) in airway resistance (sRaw) after the last Df challenge, compared with PBS exposure just before the last Df challenge in each mouse using a two-chambered, double-flow plethysmograph system (Pulmos; M.I.P.S., Osaka, Japan). We monitored ΔsRaw for 5 min after the last Df challenge. To investigate AHR, mice were forced to inhale PBS or acetyl-β-methylcholine chloride (Mch; Sigma–Aldrich, St. Louis, MO, USA) at concentrations of 3, 6, or 12.5 mg/ml. We measured sRaw in awake mice using the two-chambered, double-flow plethysmograph system. Forced inhalation was administered for 3 min. After a 1-min rest, sRaw was measured for 2 min. AHR is expressed as the concentration of Mch required to provoke a doubling of sRaw (PC200), like PC20 in patients with asthma.

Collection of blood, bronchoalveolar lavage fluid (BALF), and lung tissue

After euthanasia, blood and bronchoalveolar lavage fluid (BALF) were collected, and the lungs were removed for pathologic evaluation by hematoxylin and eosin (HE) and Periodic acid–Schiff (PAS) staining. Mucus score was estimated by PAS-stained lung. A total of 10 airways of three mice from each group were categorized according to the abundance of PAS goblet cells, and assigned numerical scores (0 = <5% goblet cells; 1 = 5–25%; 2 = 25–50%; 3 = 50–75%; 4 = >75%). Bronchoalveolar lavage (BAL) was performed 24 h after the last allergen administration, and BALF was obtained by washing the lungs with 4 × 1 ml of PBS and centrifuged. The supernatant of the first wash was stored at −80°C until use. Cell pellets of all washes were collected and resuspended in 1 ml PBS. The number of BALF cells was counted using a cell counter. Cytospin slides were stained with Diff-Quik (Sysmex, Kobe, Japan). Differential cell counts were performed on at least 400 cells.

Enzyme-linked immunosorbent assay (ELISA)

Amounts of interleukin (IL)-5, IL-10, IL-13, interferon-γ (IFN-γ), and transforming growth factor (TGF)-β1 (R&D Systems, Minneapolis, MN, USA) in the BALF were measured using an enzyme-linked immunosorbent assay (ELISA). The detection limits were 7.0 pg/mL for IL-5, 2.0 pg/mL for IL-10, 3.9 pg/mL for IL-13, 4.7 pg/mL for IFN-γ, and 4.9 pg/mL for TGF-β1. Concentrations below the detection limits were assumed to be zero for statistical analysis. Df-specific IgE was measured by ELISA as previously described.14 Briefly, diluted sera were incubated in Df extract-coated plates, followed by incubation with biotin-conjugated antibodies against IgE (Serotec, Raleigh, NC, USA) and streptavidin-horseradish peroxidase (Invitrogen, Carlsbad, CA, USA). The Df-specific serum IgE levels were expressed as relative absorbance units (optical density at 450 nm). For detection of Df-specific serum IgG1, and IgG2a, either biotinylated IgG1 (Southern Biotech, Birmingham, AL, USA) or IgG2a (BD Biosciences, San Jose, CA, USA) was used. Levels of Df-specific IgG1 and IgG2a were expressed as potency (%), which was calculated using the fluorescence intensity

![Fig. 1. Animal model and sublingual immunotherapy. BALB/c mice were intranasally sensitized with Dermatophagoides farinae (Df) extract (40 µl of 1 mg/ml) 5 days/week for 5 weeks. Negative control animals were intranasally exposed to PBS in a similar manner. Following intranasal administration of Df extract for 5 weeks, sublingual immunotherapy (SLIT) was performed 5 days/week, twice daily, for 2 weeks. Early asthmatic response (EAR) was evaluated on day 50 just after the last Df challenge. Airway hyperresponsiveness (AHR) and bronchoalveolar lavage (BAL) were evaluated on day 51, 24 h after the last Df (80 µl: 40 µl) twice of 1 mg/ml challenge.](http://dx.doi.org/10.1016/j.alit.2016.10.007)
value, as previously described. The potency (% = (sample – negative control)/(positive control – negative control) × 100. The pooled serum of Df-sensitized mice was used as a positive control.

**Evaluation of Treg**

Treg in the BALF and spleen were measured using a mouse Treg staining kit (eBioscience, San Diego, CA, USA) using a FACSCalibur® flow cytometer (BD Biosciences, San Jose, CA, USA). For Treg depletion, mice were intraperitoneally injected with PC61 monoclonal antibody (mAb, 250 µg/mouse) 3 days before the starting SLIT (day 33). Treg depletion was confirmed by evaluating the spleen for CD4, CD25, and Foxp3 expression using flow cytometry. CD25 was detected using an anti-CD25 mAb that recognizes an epitope distinct from that of the PC61 mAb. Rat IgG was used as a negative control. As previously described, no CD4+CD25+Foxp3+ cells were detected in the spleen during SLIT for 2 weeks (day 36–day 51) after PC61-treatment (day 33), whereas these cells were detected in the spleen after Rat IgG-treatment (day 33). PC61 was obtained as a kind gift from Eiichi Nakayama (Kawasaki University of Medical Welfare, Kurashiki, Japan). Rat IgG was obtained from R&D systems.

**Statistical analysis**

All data are expressed as the mean ± standard error (SEM). Statistical analysis was performed using GraphPad Prism version 6.0 for Windows (GraphPad Software, San Diego, CA, USA). The Kruskal–Wallis test with Dunn’s multiple comparisons test or the Mann–Whitney U test was used to compare values between two groups. Differences with probability values of less than 0.05 were considered significant.

**Results**

**Effects of Gal-9 on EAR and AHR in mite allergen-specific SLIT**

To evaluate the effect of Gal-9 on SLIT, we develop a SLIT model using the previously reported Df-allergen and Df-induced mouse model of chronic asthma (Fig. 1). This model exhibits EAR, AHR, chronic eosinophilic airway inflammation, Df-specific IgE, and airway remodeling like chronic atopic asthma in human. We investigated the efficacy of increasing concentrations of sublingually administered Gal-9 as an adjuvant to a specific allergen in this model. We first evaluated the EAR after exposure to a specific allergen. The airway resistance change from PBS exposure (%) at 5 min after intranasal Df challenge and AHR at 24 h after intranasal Df challenge were measured. Sublingual Df treatment alone did not significantly affect EAR and AHR, but the EAR and AHR levels tended to be lower compared with that after PBS treatment alone (p = 0.1840 and p = 0.0534, respectively, Fig. 2). Sublingual Df treatment in the presence of Gal-9 significantly reduced both EAR and AHR (p < 0.05, Fig. 2). Further, sublingual Gal-9 treatment alone did not significantly affect EAR and AHR as compared with the PBS treatment alone group (Supplementary Fig. 1A).

**Fig. 2.** Effects of Gal-9 on early asthmatic response (EAR) and airway hyperresponsiveness (AHR) in mite allergen-specific SLIT. EAR was evaluated and expressed as airway resistance change from PBS exposure (%) as described in the Methods. Airway hyperresponsiveness (AHR) was measured and expressed as PC200 sRaw (mg/ml). Data represent means ± SEM. Values shown are means from 12 mice per group. These results are typical of those obtained in three independent experiments. The Kruskal–Wallis test was used to compare values of different groups followed by Dunn’s multiple comparisons test: *p < 0.05 compared with Df-sensitization (−), SLIT: Df (−) Gal-9 (−), and Df-challenge (−) group. #p < 0.05 compared with Df-sensitization (+), SLIT: Df (−) Gal-9 (−), and Df-challenge (−) group.

**Effects of Gal-9 on airway eosinophilic inflammation in mite allergen-specific SLIT**

To evaluate the efficacy of Gal-9 on eosinophilic airway inflammation in the SLIT model, we examined inflammatory cell numbers in the BALF and histopathologic findings. Numbers of inflammatory cells in the BALF were counted 24 h after the intranasal allergen challenge. Numbers of total leukocytes and eosinophils, but not lymphocytes, neutrophils, and macrophages, were significantly reduced by SLIT in the presence of Gal-9 (p < 0.05, Fig. 3A), but not Df-alone. SLIT with Gal-9 by itself had no effect on eosinophilic airway inflammation (Supplementary Fig. 1B). Histopathologic examination of the lung tissue indicated that bronchial and perivascular eosinophilic infiltration induced by Df-challenge was suppressed by SLIT, especially in the presence of Gal-9 (Fig. 3B). Furthermore, to examine the effect of SLIT on mucus secretion in the airway, we evaluated PAS-stained lung sections. Allergen-induced mucus-secreting goblet cells were relatively suppressed by SLIT with Gal-9, especially in a low dose of Gal-9 (0.1 µg; p = 0.0008, 0.3 µg; p = 0.3683, 1.0 µg; p = 0.5483, Fig. 3C).

Gal-9 decreases Th2 cytokine levels in the BALF as well as serum IgE levels in the SLIT model

To investigate the mechanisms of the anti-inflammatory effects of Gal-9 in the SLIT model, we measured the concentrations of IL-5
A

<table>
<thead>
<tr>
<th></th>
<th>Total cells</th>
<th>Eosinophils</th>
<th>Macrophages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Df-sensitization</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>SLIT : Df</td>
<td>-</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Gal-9 (µg)</td>
<td>-</td>
<td>0.1 0.3 1.0</td>
<td>0.1 0.3 1.0</td>
</tr>
<tr>
<td>Df-challenge</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th></th>
<th>Lymphocytes</th>
<th>Neutrophils</th>
</tr>
</thead>
<tbody>
<tr>
<td>Df-sensitization</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>SLIT : Df</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>Gal-9 (µg)</td>
<td>-</td>
<td>0.1 0.3 1.0</td>
</tr>
<tr>
<td>Df-challenge</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

B

<p>| | | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Df-sensitization</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>SLIT : Df</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>Gal-9 (µg)</td>
<td>0.1</td>
<td>+</td>
</tr>
<tr>
<td>Df-challenge</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

C

<table>
<thead>
<tr>
<th></th>
<th>Mucus score</th>
</tr>
</thead>
<tbody>
<tr>
<td>Df-sensitization</td>
<td>+</td>
</tr>
<tr>
<td>SLIT : Df</td>
<td>-</td>
</tr>
<tr>
<td>Gal-9 (µg)</td>
<td>0.1 0.3 1.0</td>
</tr>
<tr>
<td>Df-challenge</td>
<td>+</td>
</tr>
</tbody>
</table>
Fig. 4. Effects of Gal-9 on Th2 cytokine levels in the BALF and serum immunoglobulin levels in the SLIT model. IL-5 and IL-13 levels in the BALF (A), and Df-specific IgE, IgG1, and IgG2a titers in the serum (B) were determined by ELISA. The detection limit was 7.0 pg/mL for IL-5 and 3.9 pg/mL for IL-13. Concentrations below the detection limits were assumed to be zero for statistical analysis. Data represent means ± SEM. Values shown are means from 12 mice per group. These results are typical of those obtained in three independent experiments. The Kruskal–Wallis test was used to compare values of different groups followed by Dunn’s multiple comparisons test. *p < 0.05 compared with Df-sensitization (−), SLIT: Df (−) Gal-9 (−), and Df-challenge (−) group. #p < 0.05 compared with Df-sensitization (+), SLIT: Df (−) Gal-9 (−), and Df-challenge (+) group.

Fig. 5. Effects of Gal-9 on Treg in the BALF in the SLIT model. TGF-β1 concentration and CD4+CD25+Foxp3high cell number in the BALF were determined by ELISA and flowcytometry, respectively. The detection limit was 4.9 pg/mL for TGF-β1. Concentrations below the detection limits were assumed to be zero for statistical analysis. Data represent means ± SEM. Values shown are means from 12 mice per group. These results are typical of those obtained in three independent experiments. The Kruskal–Wallis test was used to compare values of different groups followed by Dunn’s multiple comparisons test. *p < 0.05 compared with Df-sensitization (−), SLIT: Df (−) Gal-9 (−), and Df-challenge (−) group. #p < 0.05 compared with Df-sensitization (+), SLIT: Df (−) Gal-9 (−), and Df-challenge (+) group.
Please cite this article in press as: Ikeda M, et al., Beneficial effects of Galectin-9 on allergen-specific sublingual immunotherapy in a Dermatophagoides farinae-induced mouse model of chronic asthma, Allergology International (2016), http://dx.doi.org/10.1016/j.alit.2016.10.007
and IL-13 in the BALF by ELISA 24 h after Df-challenge. Elevated concentrations of IL-5 in the BALF were reduced by SLIT in the presence or absence of Gal-9 (p < 0.05, Fig. 4A). The IL-13 concentration in the BALF was significantly reduced by SLIT in the presence of low and medium doses of Gal-9 (p < 0.05, Fig. 4A). Furthermore, low and medium doses of Gal-9 suppressed the production of Df-specific IgE levels in the serum (p < 0.05, Fig. 4B). Serum levels of Df-specific IgG1 tended to be lower in the presence of low (p = 0.1071, Fig. 4B) and medium (p = 0.1826, Fig. 4B) doses of Gal-9. The serum levels of Df-specific IgG2a did not differ significantly among treatments (Fig. 4B). Further, SLIT with Gal-9 by itself had no effect on the BALF Th2 cytokine and serum Df-specific IgE levels (Supplementary Fig. 1C). The production of TGF-β1 in the BALF was significantly increased in this SLIT model. The TGF-β1 level was higher in the presence of low and medium doses of Gal-9 than when Df alone was administered (p = 0.0526 and p = 0.0061, respectively, Fig. 5). IL-10 and IFN-γ were not detected in the BALF of this SLIT model (data not shown). The number of CD4+CD25+Foxp3high Treg in the BALF was significantly increased by sublingual DF treatment in the presence of Gal-9 (p < 0.05, Fig. 5), but not Df-alone.

Efficacy of Gal-9 on the SLIT model was blocked by Treg depletion

To deplete Treg during SLIT, PC61 anti-CD25 mAb was injected 3 d before the starting SLIT, as described in the Methods. PC61 treatment diminished the inhibitory effects of Gal-9 on EAR and AHR (p < 0.05, Fig. 6A). PC61 treatment blocked the Gal-9 SLIT-induced decrease in the number of eosinophils, IL-5 and IL-13 concentrations in the BALF, and serum IgE levels (p < 0.05, Fig. 6B). PC61 treatment by itself had no effect on asthmatic responses in this SLIT model (Fig. 6A and B). Further, PC61 treatment suppressed the Gal-9 SLIT-induced increase in the concentration of TGF-β1 in the BALF (p < 0.05, Fig. 6C).

Discussion

The present findings demonstrated that Gal-9 enhanced the efficacy of SLIT in a mouse model of chronic asthma induced by the Df allergen. In this treatment strategy, novel SLIT using Gal-9 as an adjuvant improved the pathophysiology of asthma. The treatment in the presence of Gal-9, but not in the absence of Gal-9, significantly reduced both the EAR and AHR. Furthermore, both BALF IL-13 levels and serum Df-specific IgE levels were significantly reduced by Gal-9 as an adjuvant to the Df allergen. Gal-9 also inhibited the eosinophilic airway inflammation associated with decreased levels of the Th2 cytokines, IL-5 and IL-13.

Asthma is a common respiratory disease in humans, and more than half of patients with asthma have allergen-specific IgE.2 House dust mites are one of the most common aeroallergens in asthma.21 While inhaled corticosteroids control asthmatic symptoms well, they are not able to cure the disease. SLIT is a disease-modifying treatment for respiratory allergies,19 but the benefit and effect may not be very substantial, and the treatment requires a long period of therapy and high amounts of the allergen. Further, it is difficult to diminish allergen-specific IgE production using SLIT.20,21 Inhalation of a specific allergen might exacerbate asthma, even if asthmatic symptoms are well controlled. To cure asthma, it is important to suppress the production of allergen-specific IgE. Previous studies demonstrated the preventive effects of SLIT in a mite allergen-induced acute murine asthma model by several times (2 or 4 times) sensitization with or without alum.15,16 In the present study, we use an established model of chronic severe asthma by 25 times intranasal sensitization without alum in mice similar to human chronic asthma in adults,21 and attempted to cure this disease model by SLIT using Gal-9 as an adjuvant. Recently, Shima et al. reported that SLIT using high-dose DF extract (5 mg/day, Torii) ameliorates AHR and eosinophilic airway inflammation, but not serum IgE levels in an asthmatic mouse model.22 In the present study, we demonstrated that our new SLIT using a low dose of the same allergen (250 μg/day, Torii) with Gal-9 is more effective in a similar asthmatic mouse model. DF-specific IgE levels in the serum were significantly reduced by sublingual DF treatment in the presence of Gal-9, but not in the absence of Gal-9. Further, allergen-induced EAR and AHR were significantly suppressed by Gal-9 as an adjuvant to the DF allergen. These findings suggest that administration of Gal-9 enhances the efficacy of SLIT in mite allergen-induced asthma and might contribute to cure this disease.

SLIT induces elevated levels of IL-10 and IgG4 in the serum of patients with allergic airway diseases.21,27 Treg are thought to play an important role in the SLIT. Recent studies demonstrated that Gal-9 acts as an immunomodulator in excessive immunologic reactions by expanding Treg and enhancing TGF-β signaling.9,11 In the present study, we evaluated the regulation mechanism of the effect of Gal-9 on SLIT in addition to a specific allergen. Gal-9 may suppress eosinophilic airway inflammation by inhibiting IL-5 production in the lung or inducing apoptosis.9,22 Further, Gal-9 suppressed Df-specific IgE production by inhibiting IL-13 production, especially at low and medium doses. Next, we evaluated the levels of inhibitory cytokines in the BALF of the SLIT model. Levels of TGF-β1, but not IL-10 in the BALF were increased in sublingual DF-treated mice with low and medium doses of Gal-9 in this SLIT model. Further, numbers of CD4+CD25+Foxp3high Treg in the BALF were also increased by SLIT in the presence of Gal-9. TGF-β1 and CD4+CD25+Foxp3high Treg induced by Gal-9 in the lung might play an important role in the effects of Gal-9 on SLIT. Further studies are required to clarify the mechanisms of the adjuvant effects of Gal-9 in this SLIT model.

Gal-9 is a ligand for CD44 that blocks the binding between CD44 and its original ligand hyaluronan.23,26 Interestingly, Gal-9 binds CD44 expressed on Treg and enhances TGF-β signaling.11 Previous studies demonstrated that a medium dose of Gal-9 (1 μM) is sufficient to bind CD44 and a high dose of Gal-9 (3 μM) induces apoptosis of Th1 cells through Tim-3 signaling, and induces apoptosis of IL-5 activated human eosinophils by an unknown ligand.24,26,27 The inhibitory effect of Gal-9 on IL-13 and DF-IgE production, and Gal-9 induction of TGF-β1 were weaker at a high dose (3 μM) than at low (0.3 μM) and medium (1 μM) doses. The effects of Gal-9 on inflammatory cells may differ depending on the Gal-9 concentration by acting on a different ligand.

Treg can be depleted by treatment with PC61 anti-CD25 mAb.18 To confirm the Treg-dependent inhibitory effects of Gal-9 in this SLIT model, Treg were depleted with PC61 pretreatment during SLIT as described in the Methods. As previously described,18 during SLIT for 2 weeks, no CD4+CD25+Foxp3+ Treg were observed in the spleens of PC61-treated mice, whereas CD4+CD25+Foxp3+ Treg were observed in the spleens of Rat IgG-treated mice (data not shown). We used a low dose of Gal-9 to evaluate the contribution of Treg in the SLIT model, because a low dose of Gal-9 is more effective to induce TGF-β1 in the BALF than a high dose. The increase TGF-β1 levels in the BALF of Gal-9 SLIT mice was diminished by PC61.
pretreatment. The inhibitory effects of Gal-9 on EAR and AHR, and eosinophilic airway inflammation in this SLIT model were also diminished by PC61 pretreatment compared with Rat IgG pretreatment. Finally, the inhibitory effects of Gal-9 on the production of Ds-specific IgE in the serum were abolished by PC61 pretreatment. PC61 treatment may deplete not only CD4+ CD25hi Treg, but also CD4+CD25+ activated T cells. If the CD4+CD25+ activated T cells were mainly depleted by PC61 treatment, it would indicate that the Th2-mediated eosinophilic airway inflammation was decreased. The Th2 mediated eosinophilic airway inflammation, however, was increased by PC61 treatment. In this model, the effects of Treg depletion were mainly observed, even if activated T cells were also depleted. Further, PC61 treatment by itself and SLIT with Gal-9 by itself had no effect on asthmatic responses in this SLIT model. These data suggest that the inhibitory effects of Gal-9 on asthmatic responses are Treg and Df allergen-dependent. Further studies are required to clarify the mechanisms of inhibitory effects of Gal-9 including TGF-β1 production in detail.

In conclusion, Gal-9 inhibited not only Th2-related eosinophilic airway inflammation, but also allergen-induced EAR and allergen-specific IgE production in this SLIT model. SLIT using Gal-9 as an adjuvant might cure asthma more effectively than SLIT without Gal-9, and Gal-9 is an adjuvant that might shorten the therapy period and reduce the amount of allergen required in the SLIT.

Acknowledgements

The authors thank Ms. Mariko Takaya, and Ms. Tae Uesaka for their skillful assistance. This work was supported in part by JSPS KAKENHI JP26461205 and by the Project Research Grants from Kawasaki Medical School.

Appendix A. Supplementary data

Supplementary data related to this article can be found at http://dx.doi.org/10.1016/j.alit.2016.10.007.

Conflict of interest

AH and KD-D are employees of Torii Pharmaceutical Co., Ltd. The rest of the authors have no conflict of interest.

Authors’ contributions

SK, KD-D, and MO designed the study. MI, AH, HS, and SK performed the experiments. MI and SK wrote the paper.

References